nach oben

Erschienen in:

01.12.2008 | Original Article

Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation

verfasst von: Junichi Sugita, Junji Tanaka, Aya Hashimoto, Souichi Shiratori, Atsushi Yasumoto, Kentaro Wakasa, Misato Kikuchi, Akio Shigematsu, Yoko Miura, Yutaka Tsutsumi, Takeshi Kondo, Masahiro Asaka, Masahiro Imamura

Erschienen in: Annals of Hematology | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

We retrospectively analyzed very early chimerism before and ongoing neutrophil engraftment (days 7, 14, 21, 28) and investigated the influence of conditioning regimens and stem cell sources on donor-type chimerism in 59 Japanese patients who had received allogeneic hematopoietic stem cell transplantation. The percentage of donor-type chimerism increased before engraftment in all patients who achieved engraftment. The average percentage of donor-type chimerism in patients who had received reduced-intensity stem cell transplantation (RIST) with total body irradiation (TBI) was significantly higher than that in patients who had received RIST without TBI (98.8% vs 87.5% on day 21, P < 0.01; 99.3% vs 84.3% on day 28, P < 0.01). The average percentage of donor-type chimerism after peripheral blood stem cell transplantation was significantly higher than that after bone marrow transplantation on day 7 (81.5% vs 43.1%, P < 0.01), and the average percentage of donor-type chimerism after cord blood transplantation was significantly lower on day 14 (55.8% vs 84.8%, P < 0.05). Compared with the average percentage of donor-type chimerism in patients who achieved engraftment with each stem cell source, a notable decrease in donor-type chimerism was observed in patients who failed to achieve engraftment. This study suggests that differences in conditioning regimens and stem cell sources should be taken into account when considering donor-type chimerism.

Balon J, Halaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A et al (2005) Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant 35:1083–1088 doi:10.1038/sj.bmt.1704962 PubMedCrossRef

Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE (2003) Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102:1915–1919 doi:10.1182/blood-2002-11-3337 PubMedCrossRef

Baron F, Sandmaier BM (2006) Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 20:1690–1700 doi:10.1038/sj.leu.2404335 PubMedCrossRef

Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al (2000) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18–29 doi:10.1046/j.1365-2141.2000.02196.x PubMedCrossRef

Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234–3241PubMed

Galimberti S, Benedetti E, Morabito F, Fazzi R, Pacini S, Andreazzoli F et al (2005) Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Transpl Immunol 15:173–177 doi:10.1016/j.trim.2005.06.002 PubMedCrossRef

Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631–637 doi:10.1182/blood.V97.3.631 PubMedCrossRef

Gleissner B, Blau IW, Sindram A, Reinhardt R, Knauf W, Thiel E (2001) Analysis of chimerism during the early period after allogeneic peripheral stem cell transplantation. Clin Lab Haematol 23:401–406 doi:10.1046/j.1365-2257.2001.00408.x PubMedCrossRef

Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF (2007) Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 39:285–291 doi:10.1038/sj.bmt.1705582 PubMedCrossRef

10.

Jaksch M, Uzunel M, Remberger M, Sundberg B, Mattsson J (2005) Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II–IV. Clin Transplant 19:346–349 doi:10.1111/j.1399-0012.2005.00345.x PubMedCrossRef

11.

Keil F, Prinz E, Moser K, Mannhalter C, Kalhs P, Worel N et al (2003) Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation 76:230–236 doi:10.1097/01.TP.0000071862.42835.76 PubMedCrossRef

12.

Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A et al (2004) Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant 33:697–702 doi:10.1038/sj.bmt.1704425 PubMedCrossRef

13.

Lassaletta A, Ramirez M, Montero JM, Gonzalez-Vicent M, Balas A, Madero L et al (2005) Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Leukemia 19:504–506PubMed

14.

Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al (2004) Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351:2265–2275 doi:10.1056/NEJMoa041276 PubMedCrossRef

15.

McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390–3400 doi:10.1182/blood.V97.11.3390 PubMedCrossRef

16.

Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D et al (2006) Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transplant 37:837–843 doi:10.1038/sj.bmt.1705352 PubMedCrossRef

17.

Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Masmas TN, Dickmeiss E et al (2004) Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease. Biol Blood Marrow Transplant 10:337–346 doi:10.1016/j.bbmt.2004.01.003 PubMedCrossRef

18.

Ritchie DS, Morton J, Szer J, Roberts AW, Durrant S, Shuttleworth P et al (2003) Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 9:435–442 doi:10.1016/S1083-8791(03)00128-9 PubMedCrossRef

19.

Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al (2004) Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351:2276–2285 doi:10.1056/NEJMoa041469 PubMedCrossRef

20.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763PubMed

21.

Stem cell Trialists’ Collaborative Group (2005) Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23:5074–5087CrossRef

22.

Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al (2004) Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104:3813–3820 doi:10.1182/blood-2004-03-1001 PubMedCrossRef

23.

Tsutsumi Y, Tanaka J, Kato N, Zhang L, Mori A, Kobayasi R et al (2002) Analysis of mixed chimerism in patients after allogeneic stem cell transplantation using a capillary electrophoresis system. Acta Haematol 107:195–202 doi:10.1159/000058314 PubMedCrossRef

24.

Tsutsumi Y, Tanaka J, Sugita J, Kato N, Zhang L, Yonezumi M et al (2002) Analysis of T-cell repertoire and mixed chimaerism in a patient with aplastic anaemia after allogeneic bone marrow transplantation. Br J Haematol 118:136–139 doi:10.1046/j.1365-2141.2002.03628.x PubMedCrossRef

25.

Valcarcel D, Martino R, Caballero D, Mateos MV, Perez-Simon JA, Canals C et al (2003) Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 31:387–392 doi:10.1038/sj.bmt.1703846 PubMedCrossRef

Titel: Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation
verfasst von: Junichi Sugita
Junji Tanaka
Aya Hashimoto
Souichi Shiratori
Atsushi Yasumoto
Kentaro Wakasa
Misato Kikuchi
Akio Shigematsu
Yoko Miura
Yutaka Tsutsumi
Takeshi Kondo
Masahiro Asaka
Masahiro Imamura
Publikationsdatum: 01.12.2008
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 12/2008
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0542-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2008

The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas

The application of conventional cytogenetics, FISH, and RT-PCR to detect genetic changes in 70 children with ALL

Platelet production rate predicts the response to prednisone therapy in patients with idiopathic thrombocytopenic purpura

Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis

Breast and pelvic masses in a myeloma patient

Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden